Sharif Nadim, Ahmed Shamsun Nahar, Opu Rubayet Rayhan, Tani Mahmuda Rahman, Dewan Dolly, Daullah Muktasid Ud, Shanto Rakibul Islam, Parvez Anowar Khasru, Talukder Ali Azam, Dey Shuvra Kanti
Department of Microbiology, Jahangirnagar University, Savar, Dhaka, 1342, Bangladesh.
Department of Microbiology, Jahangirnagar University, Savar, Dhaka, 1342, Bangladesh.
Diabetes Metab Syndr. 2021 May-Jun;15(3):1009-1016. doi: 10.1016/j.dsx.2021.05.005. Epub 2021 May 8.
Patients with coronavirus disease-2019 (COVID-19) with preexisting diabetes and cardiovascular metabolic diseases have higher fatality rate. The circulation of new variants with emerging clinical characteristics requires more studies focusing the impact of preexisting health conditions on outcome of COVID-19 accurately.
Main aim of this study was to investigate the impact of diabetes and cardiovascular disease (CVD) on disease prognosis and severe health outcomes among patients with COVID-19.
A retrospective study was performed on 799 patients with COVID-19 during December 10, 2020, to February 10, 2020 in Bangladesh. Logistic regression analysis was performed for age, sex, diabetes, CVD and symptoms on fatality. Kaplan-Meier survival analysis was conducted to predict the survival rate.
Fatality was detected in 40% (318 of 799) patients with COVID-19. Among 318 fatalities, 90.6% were detected in patients with CVD and 74.5% in patients with diabetes. Case fatality rate was highest in patients with COVID-19, CVD and diabetes (94, 184 of 195). Fever (91%) and dry cough (71%) were the most frequent symptoms. CVD (42.2%), diabetes (32.7%) and obesity (18%) were prevalent. The highest odds of risk was detected in patients with COVID-19, CVD and diabetes (OR: 6.98, 95% CI, 4.21 to 7.34). Female patients had the highest survival rate.
In this study, 318 fatality was seen in 799 patients with COVID-19. The highest odds of fatality risk was detected in patients with COVID-19, CVD and diabetes. The risk increased many folds when CVD and diabetes coexisted in patients.
患有2型糖尿病和心血管代谢疾病的2019冠状病毒病（COVID-19）患者死亡率更高。具有新出现临床特征的新变种的传播需要更多研究来准确聚焦既往健康状况对COVID-19结局的影响。
本研究的主要目的是调查糖尿病和心血管疾病（CVD）对COVID-19患者疾病预后和严重健康结局的影响。
对2020年12月10日至2020年2月10日期间孟加拉国的799例COVID-19患者进行了一项回顾性研究。对年龄、性别、糖尿病、CVD和症状进行了关于死亡率的逻辑回归分析。进行了Kaplan-Meier生存分析以预测生存率。
在799例COVID-19患者中，40%（318例）检测到死亡。在318例死亡病例中，90.6%在CVD患者中检测到，74.5%在糖尿病患者中检测到。COVID-19、CVD和糖尿病患者的病死率最高（195例中的94例、184例）。发热（91%）和干咳（71%）是最常见的症状。CVD（42.2%）、糖尿病（32.7%）和肥胖（18%）较为普遍。COVID-19、CVD和糖尿病患者的风险几率最高（比值比：6.98，95%置信区间，4.21至7.34）。女性患者的生存率最高。
在本研究中，799例COVID-19患者中有318例死亡。COVID-19、CVD和糖尿病患者的死亡风险几率最高。当CVD和糖尿病在患者中共存时，风险增加了许多倍。
